Hapvida: profit up 23.8%, but revenue growth slowed to 11.4%
Contents
In its Q3 2026 report, Hapvida posted revenue of $1,619.2m, EBITDA of $157.6m and net profit of $19.8m. Year on year, revenue grew 11.4%, EBITDA 13.0% and net profit 23.8%. Revenue growth slowed from 14.7% in Q2 2026. Our conclusion: the share is fairly valued – the portal model puts upside to fair value at just +5%. Our view: the share is fairly valued; upside on the portal model +5%.
Our view: is there upside
Our view in numbers
| Metric | Our read |
|---|---|
| Verdict | Neutral |
| Upside on the portal model | +5% |
| How the model works | fundamental value-creation model: EBITDA growth times the target multiple, against market cap |
| Net debt / EBITDA | 1.78 – moderate leverage |
| Strongest case for | Operating cash flow of $103.7m covers capital expenditure of $32.4m more than threefold, and EBITDA is growing 13.0%. |
| Strongest case against | Revenue growth slowed to 11.4% from 14.7%, and net profit remains low at $19.8m with a 1.2% margin. |
| What would change the view | If revenue growth accelerates above 14.7% or net debt falls from $1.0bn, the verdict could rise to 'rather attractive'. |
Key takeaways
— Revenue grew 11.4% year on year, but that is slower than the 14.7% a quarter earlier
— EBITDA added 13.0%, lifting the margin to 9.7% from 9.6% a year earlier
— Net profit rose 23.8% to $19.8m, but its margin remains low at 1.2%
— Operating cash flow of $103.7m covered capital expenditure of $32.4m more than threefold
— Net debt rose from $0.7bn to $1.0bn over 12 months, and its ratio to LTM EBITDA stands at 1.78
— The EV/EBITDA LTM multiple of 2.67 looks low, but the portal model shows only +5% upside to fair value
Key figures, USD bn
| Metric | Q3 2025 | Q3 2026 | Change |
|---|---|---|---|
| Revenue | 1.45 | 1.62 | +11.4% |
| EBITDA | 0.14 | 0.16 | +13.0% |
| Operating profit | 0.06 | 0.09 | +46.3% |
| Net profit | 0.02 | 0.02 | +23.8% |
| Operating cash flow | 0.05 | 0.10 | +102.8% |
| Capex | 0.04 | 0.03 | -21.5% |
| EBITDA margin | 9.6% | 9.7% | +0.1 pp |
| Net margin | 1.1% | 1.2% | +0.1 pp |
Revenue grew 11.4% year on year, but that is slower than the 14.7% a quarter earlier
In Q3 2026, Hapvida's revenue came to $1,619.2m, up 11.4% year on year. A quarter earlier, in Q2 2026, growth was higher at 14.7%. The slowdown came against a rising base: revenue has grown sequentially every quarter since Q4 2024.
Over the last 12 months, revenue reached $6,200.0m. That sets the scale of the business, but its growth rate is now more modest than at the start of 2026. The report does not disclose the reasons for the slowdown, so we can only note that the absolute quarterly increase in revenue shrank from $75.5m in Q2 to $8.1m in Q3.
Revenue and EBITDA by quarter
| Period | Measure | bn USD |
|---|---|---|
| Q4 2024 | Revenue | 1.269725 |
| Q1 2025 | Revenue | 1.333604 |
| Q2 2025 | Revenue | 1.404965 |
| Q3 2025 | Revenue | 1.4531749999999999 |
| Q4 2025 | Revenue | 1.4630830000000001 |
| Q1 2026 | Revenue | 1.535653 |
| Q2 2026 | Revenue | 1.611107 |
| Q3 2026 | Revenue | 1.619181 |
| Q4 2024 | EBITDA | 0.12808499999999998 |
| Q1 2025 | EBITDA | 0.18780700000000003 |
| Q2 2025 | EBITDA | 0.09854700000000001 |
| Q3 2025 | EBITDA | 0.139526 |
| Q4 2025 | EBITDA | 0.111417 |
| Q1 2026 | EBITDA | 0.162856 |
| Q2 2026 | EBITDA | 0.136952 |
| Q3 2026 | EBITDA | 0.15761599999999998 |
EBITDA margin
| Period | Measure | % |
|---|---|---|
| Q4 2024 | EBITDA margin | 10.1 |
| Q1 2025 | EBITDA margin | 14.1 |
| Q2 2025 | EBITDA margin | 7.0 |
| Q3 2025 | EBITDA margin | 9.6 |
| Q4 2025 | EBITDA margin | 7.6 |
| Q1 2026 | EBITDA margin | 10.6 |
| Q2 2026 | EBITDA margin | 8.5 |
| Q3 2026 | EBITDA margin | 9.7 |
EBITDA added 13.0%, lifting the margin to 9.7% from 9.6% a year earlier
EBITDA for Q3 2026 was $157.6m, up 13.0% year on year. EBITDA growth outpaced revenue growth, lifting the EBITDA margin to 9.7% from 9.6% a year earlier. It is a small improvement, but it shows the company is keeping costs in check.
Operating profit for the quarter was $94.3m. It grew faster than EBITDA in percentage terms, pointing to lower depreciation relative to revenue. Still, the absolute operating margin remains modest at around 5.8% of revenue.
Net profit by quarter
| Period | Measure | bn USD |
|---|---|---|
| Q4 2024 | Net profit | −0.043232999999999994 |
| Q1 2025 | Net profit | 0.031765999999999996 |
| Q2 2025 | Net profit | −0.058508000000000004 |
| Q3 2025 | Net profit | 0.015987 |
| Q4 2025 | Net profit | −0.015506 |
| Q1 2026 | Net profit | −0.019146999999999997 |
| Q2 2026 | Net profit | −0.015018 |
| Q3 2026 | Net profit | 0.019796 |
Net profit rose 23.8% to $19.8m, but its margin remains low at 1.2%
Hapvida's net profit for Q3 2026 was $19.8m, up 23.8% year on year. The net margin rose to 1.2% from 1.1%. Such profit growth on a modest margin change is explained by the low base: each additional dollar of profit produces a large percentage gain.
Profit grew faster than EBITDA, which implies lower financial expenses or a lower tax burden relative to operating profit. The report does not break these items down, so we cannot say which factor was decisive. What matters is that net profit remains small relative to revenue at 1.2%, and any deterioration in the operating picture could quickly wipe it out.
Net debt
at each reporting date, current net debt / EBITDA (LTM) = 1.78
| Period | Measure | bn USD |
|---|---|---|
| Q4 2024 | Net debt | 0.6427849999999999 |
| Q1 2025 | Net debt | 0.638477 |
| Q2 2025 | Net debt | 0.647419 |
| Q3 2025 | Net debt | 0.724248 |
| Q4 2025 | Net debt | 0.909566 |
| Q1 2026 | Net debt | 0.952896 |
| Q2 2026 | Net debt | 0.970573 |
| Q3 2026 | Net debt | 1.014141 |
Operating cash flow of $103.7m covered capital expenditure of $32.4m more than threefold
Operating cash flow for Q3 2026 was $103.7m, while capital expenditure was $32.4m. Free cash flow therefore exceeded $71m. This is a strong part of the report: the business generates enough cash to fund investment and service debt.
Over the last 12 months, operating cash flow reached $339.1m. With quarterly capex of $32.4m, annual investment remains moderate. Still, capex can be uneven: in Q4 2025 it was $77.9m, well above the current level.
Net debt rose from $0.7bn to $1.0bn over 12 months, and its ratio to LTM EBITDA stands at 1.78
Hapvida's net debt at 30 September 2026 was $1,014.1m. A year earlier, at 30 September 2025, it stood at $0.7bn, so it rose by $0.3bn over 12 months. The ratio of net debt to LTM EBITDA is 1.78. That is a moderate level and does not create acute pressure on the finances.
Debt rose against strong operating cash flow, which may point to funding investment or shareholder payouts. The report gives no breakdown, so we simply state the debt level and its ratio to EBITDA. For a company with a market capitalisation of about $502.5m, net debt of $1.0bn means debt is twice the equity value.
The EV/EBITDA LTM multiple of 2.67 looks low, but the portal model shows only +5% upside to fair value
The EV/EBITDA LTM multiple for Hapvida is 2.67. That is a very low level compared with typical valuations, but the company carries high debt, and the market appears to be pricing in risks. Market capitalisation is $502.5m, while net debt is $1.0bn, which together form enterprise value.
On the portal's model, the share's fair value implies upside of +5%. This is our own calculation based on EBITDA growth and a target multiple. Such upside is close to zero and means the share is fairly valued. For comparison, return on equity (ROE) is just 0.85%, which also gives no reason to expect rapid value growth.
Valuation on the latest reported figures
| Metric | Value |
|---|---|
| Market cap | 0.50 bn USD |
| EV/EBITDA (LTM) | 2.7 |
| P/B | 0.06 |
| Net debt / EBITDA (LTM) | 1.78 |
| Operating cash flow (LTM) | 0.34 bn |
| ROE | 0.9% |
Bottom line
The strong point of the report was operating cash flow of $103.7m, which covered capital expenditure more than threefold. EBITDA grew 13.0% and the margin rose to 9.7%. However, revenue growth slowed to 11.4%, and net profit remains low at $19.8m with a 1.2% margin. Leverage at 1.78x EBITDA is moderate, but net debt is twice the market capitalisation. Our conclusion: the share is fairly valued – the portal model puts upside to fair value at just +5%. Our view: the share is fairly valued; upside on the portal model +5%.